TRIDUCARD PILLS 35MG

$12.30
No tax

TRIDUCARD PILLS 35MG - 60 tabs

Quantity

 

Security policy (edit with Customer reassurance module)

 

Delivery policy (edit with Customer reassurance module)

 

Return policy (edit with Customer reassurance module)

International non-proprietary name:

trimetazidine

Dosage Form:

film release coated release tablets.

Composition:

one pill with a modified release, film-coated, contains the active substance Trimetazidine dihydrochloride 35 mg.

Excipients:

hypromellose (methocel K 4M Premium EP) - 54 mg; microcrystalline cellulose - 118 mg; colloidal silicon dioxide (aerosil) - 1 mg; Magnesium stearate - 1 mg;

Shell composition:

Hydroxypropyl methylcellulose (hypromellose) - 4,628 mg; talc - 0.357 mg; titanium dioxide -1,002 mg; macrogol (polyethylene oxide 4000) - 1,002 mg; Azorubine dye (acid red 2C for pharmaceutical purposes) - 0.011 mg.

Pharmacotherapeutic group:

antihypoxic drug.

Pharmacological properties Pharmacodynamics:

Trimetazidine has an antianginal, antihypoxic effect. Directly affecting the cardiomyocytes and neurons of the brain, optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinine.Under conditions of acidosis, it normalizes the functioning of ion channels, prevents the accumulation of Calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate concentration due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage. When angina reduces the frequency of attacks (reduced consumption of nitrates), after 2 weeks of treatment increases exercise tolerance, reduced blood pressure drops. It improves hearing and the results of vestibular samples in patients, reduces dizziness and tinnitus. When vascular pathology of the eye restores the functional activity of the retina.

Pharmacokinetics:

After taking the drug inside trimetazidine quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. The time to reach the maximum concentration in the blood plasma is 2 hours. The maximum concentration after a single dose of 35 mg of trimetazidine is about 55 ng / ml. Easily passes through histohematogenous barriers. The half-life (T1 / 2) is 4.5-5 hours. Communication with plasma proteins - 16%. Excreted by the kidneys (about 60% - unchanged).

Indications for use:

 - Ischemic heart disease: prevention of angina attacks (in combination therapy);

- chorioretinal vascular disorders;

- Vertigo vascular origin;

- Cochleo-vestibular disorders of the ischemic nature (tinnitus, hearing loss)

Contraindications:

- Hypersensitivity to any component of the drug;

- Renal failure (creatinine clearance below 15 ml / min);

- Severe abnormal liver function;

- Pregnancy;

- The period of breastfeeding;

- Age up to 18 years (efficacy and safety have not been established).

Dosage and administration.

Inside, while eating. The recommended dosage regimen of 2 pills (70 mg) per day, in 2 doses. The course of treatment on the advice of a doctor.

Side effect.

Allergic reactions (pruritus). Rarely from the gastrointestinal tract: gastralgia, nausea, vomiting; headache, feeling of palpitations.

Overdose.

Currently, no cases of overdose have been reported.

Special instructions.

The drug is not intended for the relief of strokes! In the case of an attack of angina, treatment should be reviewed and adapted (drug therapy or revascularization). The use of the drug does not affect the ability to drive and perform work that requires a high speed of mental and physical reactions.

Form release.

Film-coated modified release tablets, 35 mg. 10 or 30 pills in a blister pack.On 30, 60, 90, 120, 180, 300 in a polymer can or in a polymer bottle. Each can or bottle, 3, 6 blister packs of 10 pills or 1, 2, 3, 4, 6, 10 blister packs of 30 pills along with instructions for use are placed in a pack of cardboard.

Storage conditions.

In a dry, dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.

31 Items